Compare HAFC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | CSTL |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.0M | 806.3M |
| IPO Year | 2000 | 2019 |
| Metric | HAFC | CSTL |
|---|---|---|
| Price | $25.72 | $25.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $31.33 | ★ $47.17 |
| AVG Volume (30 Days) | 212.8K | ★ 396.6K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ 22.44 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | $270,165,000.00 | ★ $344,229,000.00 |
| Revenue This Year | $18.65 | $2.42 |
| Revenue Next Year | $7.28 | $12.69 |
| P/E Ratio | $10.06 | ★ N/A |
| Revenue Growth | ★ 15.28 | 3.66 |
| 52 Week Low | $19.25 | $14.59 |
| 52 Week High | $30.20 | $44.28 |
| Indicator | HAFC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 29.22 |
| Support Level | $24.44 | $24.89 |
| Resistance Level | $27.04 | $34.97 |
| Average True Range (ATR) | 0.71 | 1.07 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 48.82 | 18.08 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.